• BetterLife Pharma pivoted its lead asset BETR-001 to target migraine and other primary headache disorders as its main development focus.
• Strategy shifts BETR-001 away from near-term psychiatric indications, retaining depression and other disorders as longer-dated optional programs.
• Company expects to file an IND for BETR-001 in 1Q 2027; FDA pre-IND meeting completed, IND-enabling toxicity study started.
• BETR-001 is a non-hallucinogenic, oral 5-HT2A partial agonist derived from 2-bromo-LSD, positioned as a non-scheduled outpatient therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BetterLife Pharma Inc. published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein.